STOCK TITAN
  1. Home
  2. News
  3. ALXO

Alx Oncology Holdings Inc - ALXO STOCK NEWS

IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
earnings
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Announces November Investor Conference Participation
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
offering
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Announces Pricing of Public Offering
offering
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Announces Proposed Public Offering
offering
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
clinical trial
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
conferences clinical trial
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Realigns Executive Leadership Team
management
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Announces September Investor Conference Participation
IMPACT
SENTIMENT
ALXO : Nasdaq
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
earnings
Stock ALXO logo
Alx Oncology Holdings Inc

Nasdaq:ALXO

ALXO Rankings

#3687 Ranked by Market Cap
#4509 Ranked by Stock Gains
N/A Ranked by Dividends

ALXO Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About ALXO

alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com